| Circular RNAs are abundant, conserved, and associated with ALU repeats WR Jeck, JA Sorrentino, K Wang, MK Slevin, CE Burd, J Liu, WF Marzluff, ... Rna 19 (2), 141-157, 2013 | 2486 | 2013 |
| Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk CE Burd, WR Jeck, Y Liu, HK Sanoff, Z Wang, NE Sharpless PLoS Genet 6 (12), e1001233, 2010 | 819 | 2010 |
| Expression of p16INK4a in peripheral blood T‐cells is a biomarker of human aging Y Liu, HK Sanoff, H Cho, CE Burd, C Torrice, JG Ibrahim, NE Thomas, ... Aging cell 8 (4), 439-448, 2009 | 333 | 2009 |
| INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis Y Liu, HK Sanoff, H Cho, CE Burd, C Torrice, KL Mohlke, JG Ibrahim, ... PloS one 4 (4), e5027, 2009 | 278 | 2009 |
| Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model CE Burd, JA Sorrentino, KS Clark, DB Darr, J Krishnamurthy, AM Deal, ... Cell 152 (1-2), 340-351, 2013 | 261 | 2013 |
| The Xenoestrogen Bisphenol A Induces Inappropriate Androgen Receptor Activation and Mitogenesis in Prostatic Adenocarcinoma Cells 1 This work was supported by NIH Training … YB Wetherill, CE Petre, KR Monk, A Puga, KE Knudsen Molecular cancer therapeutics 1 (7), 515-524, 2002 | 239 | 2002 |
| The molecular balancing act of p16INK4a in cancer and aging KM LaPak, CE Burd Molecular Cancer Research 12 (2), 167-183, 2014 | 200 | 2014 |
| Fisetin is a senotherapeutic that extends health and lifespan MJ Yousefzadeh, Y Zhu, SJ McGowan, L Angelini, ... EBioMedicine 36, 18-28, 2018 | 198 | 2018 |
| Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity CE Petre, YB Wetherill, M Danielsen, KE Knudsen Journal of Biological Chemistry 277 (3), 2207-2215, 2002 | 163 | 2002 |
| Liposomal daunorubicin as treatment for Kaposi’s sarcoma CE Petre, DP Dittmer International journal of nanomedicine 2 (3), 277, 2007 | 135 | 2007 |
| Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation CJ Burd, CE Petre, LM Morey, Y Wang, MP Revelo, CA Haiman, S Lu, ... Proceedings of the National Academy of Sciences 103 (7), 2190-2195, 2006 | 132 | 2006 |
| An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation GP Souroullas, WR Jeck, JS Parker, JM Simon, JY Liu, J Paulk, J Xiong, ... Nature medicine 22 (6), 632, 2016 | 120 | 2016 |
| Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy CE Petre, SH Sin, DP Dittmer Journal of virology 81 (4), 1912-1922, 2007 | 120 | 2007 |
| Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma CE Burd, W Liu, MV Huynh, MA Waqas, JE Gillahan, KS Clark, K Fu, ... Cancer discovery 4 (12), 1418-1429, 2014 | 117 | 2014 |
| Differential requirement of SWI/SNF for androgen receptor activity TW Marshall, KA Link, CE Petre-Draviam, KE Knudsen Journal of Biological Chemistry 278 (33), 30605-30613, 2003 | 115 | 2003 |
| Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression CJ Burd, CE Petre, H Moghadam, EM Wilson, KE Knudsen Molecular Endocrinology 19 (3), 607-20, 2005 | 92 | 2005 |
| Specificity of cyclin D1 for androgen receptor regulation CE Petre-Draviam, SL Cook, CJ Burd, TW Marshall, YB Wetherill, ... Cancer research 63 (16), 4903-4913, 2003 | 81 | 2003 |
| A central domain of cyclin D1 mediates nuclear receptor corepressor activity CE Petre-Draviam, EB Williams, CJ Burd, A Gladden, H Moghadam, ... Oncogene 24 (3), 431-444, 2005 | 68 | 2005 |
| Distinct p53, p53: LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas W Chen, IB Hilton, MR Staudt, CE Burd, DP Dittmer Journal of virology 84 (8), 3898-3908, 2010 | 67 | 2010 |
| p16INK4a reporter mice reveal age-promoting effects of environmental toxicants JA Sorrentino, J Krishnamurthy, S Tilley, JG Alb, CE Burd, NE Sharpless The Journal of clinical investigation 124 (1), 169-173, 2014 | 59 | 2014 |
Norman E. SharplessDirector, The National Cancer InstituteVerified email at nih.gov
